0001428336-21-000002.txt : 20210111 0001428336-21-000002.hdr.sgml : 20210111 20210111090723 ACCESSION NUMBER: 0001428336-21-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210111 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210111 DATE AS OF CHANGE: 20210111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 21519485 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20210111.htm 8-K hqy-20210111
0001428336false00014283362021-01-112021-01-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 11, 2021

HEALTHEQUITY, INC.


Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 7.01    Regulation FD Disclosure
On January 11, 2021, HealthEquity, Inc. (the "Company") issued a press release, attached as Exhibit 99.1 to this current report on Form 8-K, announcing its estimated year-end sales results for its fiscal year ending January 31, 2021 and that it will discuss these results and estimates during its virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 5:20 PM Eastern Time. A live audio webcast of the presentation along with a copy of the Company's presentation material from the conference will be available through the investor page at the Company website: ir.healthequity.com.
The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits
(d) Exhibits






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHEQUITY, INC.
Date: January 11, 2021By:/s/ Darcy Mott
Name:Darcy Mott
Title:Executive Vice President and Chief Financial Officer



EX-99.1 2 jpmhccconf2021.htm EX-99.1 Document

image_01a.jpg

HealthEquity Announces Year-End Sales Outlook,
Presentation at JP Morgan Healthcare Conference
Draper, Utah – (GLOBE NEWSWIRE) – January 11, 2021 – HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest independent health savings account (“HSA") custodian, today announced it will provide final sales results for its fiscal year 2021, on February 8, 2021, while providing estimates of HSA members, HSA assets and Total Accounts for its fiscal year ending on January 31, 2021, and raised its outlook for HSA cash yield for fiscal year 2022. HealthEquity also announced its JP Morgan Health Conference virtual presentation time and access.
Estimated HSA members are expected to be in a range between 5.7 million to 5.8 million by January 31, 2021, up from 5.3 million a year earlier.
HSA assets are expected to be in a range of $13.6 billion to $13.8 billion, up from $11.5 billion at the end of the prior year.
HSA cash is expected to be in a range of $9.6 billion to $9.7 billion by January 31, 2021, up from $8.7 billion a year earlier.
HSA investments are expected to be in a range of $4.0 billion to $4.1 billion, excluding the potential impact from market volatility for the remainder of the month of January 2021, compared to $2.8 billion at the end of fiscal year 2020.
HealthEquity estimates it will close fiscal year 2021 with Total Accounts in the range of 12.8 to 13.0 million, not including ~0.6 million commuter accounts in suspense due to the pandemic, compared to 12.8 million at the end of the prior year.
The Company estimates that it will end its fiscal 2021 year with approximately 100,000 employer clients and 174 network partners consisting of integrated health and retirement plan partners, brokers and benefit advisors.
The Company further announced that with a large part of HSA cash now placed and based upon current indications provided by its bank depository partners, it now expects the yield on HSA cash with yield to be between 1.75% to 1.80% for fiscal year 2022.
Commenting on the results, Jon Kessler, President and CEO said, “The team made the most of its opportunities during fiscal year 2021 and we expect to grow HSAs, HSA assets and Total Accounts on par with or ahead of fiscal year 2020 as a result of their efforts. The uptake of our total solution for HSA and other consumer directed benefit administration, and the pipeline of prospects that deferred change during the pandemic leave us excited for the sales growth HealthEquity can achieve in the year ahead.”
HealthEquity will discuss these results and estimates during its virtual presentation at the 39th Annual JP Morgan Healthcare Conference on Wednesday, January 13, 2021. Jon Kessler, President and Chief Executive Officer, Darcy Mott, Executive Vice President and Chief Financial Officer, and Tyson Murdock, Executive Vice President and Deputy Chief Financial Officer will discuss HealthEquity in a presentation scheduled to begin at 5:20 PM Eastern Time and will be available for virtual one-on-one meetings throughout the conference.
A live audio webcast of the presentation along with a copy of the presentation slides will be available and archived on HealthEquity’s investor relations website at http://ir.healthequity.com.




About HealthEquity
HealthEquity administers Health Savings Accounts (HSAs) and other consumer-directed benefits for our more than 12 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
the impact of the ongoing COVID-19 pandemic on the Company, its operations and its financial results;
our ability to realize the anticipated financial and other benefits from combining the operations of WageWorks with our business in an efficient and effective manner;
our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
the significant competition we face and may face in the future, including from those with greater resources than us;
our reliance on the availability and performance of our technology and communications systems;
recent and potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
our reliance on partners and third-party vendors for distribution and important services;
our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
our ability to protect our brand and other intellectual property rights; and
our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2020, as updated by our Quarterly Report on Form 10-Q for the quarter ended October 31, 2020,



and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact:
Richard Putnam
801-727-1209
rputnam@healthequity.com


EX-101.SCH 3 hqy-20210111.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 hqy-20210111_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 hqy-20210111_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 hqy-20210111_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover page. Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 hqy-20210111_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 image_01a.jpg begin 644 image_01a.jpg MB5!.1PT*&@H -24A$4@ !1D #;" 8 #IGI:> "7!(67, $SE M !,Y0%USO"5 G=$E$051XG.W888ZC.8Z$X3[07FBOLQ??Q2#16$^/LNS/ M$AF,T/L _-5566*05K;UU_\" ( (__U?_R,M /?ZBXME/F8$ /@&OS=R MJ;] 4G4% +NXQP"H\,AH@!D!Z,9]DX$YYE)_@:3J"@!V<8\!4.&1T0 S M"- M^R8#<\RE_@))U14 [.(> Z#"(Z,!9@2@&_=-!N:82_T%DJHK -C%/09 A4=& M \P(0#?NFPS,,9?Z"R155P"PBWL,@ J/C :8$8!NW#<9F&,N]1=(JJX 8!?W M& 5'AD-,", W;AO,C#'7.HOD%1= < N[C$ *CPR&F!& +IQWV1@CKG47R"I MN@* 7=QC %1X9#3 C !TX[[)P!QSJ;] 4G4% +NXQP"H\,AH@!D!Z,9]DX$Y MYE)_@:3J"@!V<8_]( .@'X^,!I@1@&[<-QF88R[E%R>JM@!@%_?8#S( ^O'( M:( 9 >C&?9.!.>92?G&B:@L =G&/_2 #H!^/C :8$8!NR?=-:E\KR7.\7<<7 M)$I3 +"+>^P'&0#]>&0TP(P =$N^;U+[6DF>X^TZOB!1F@* 7=QC/\@ Z,+N.+TB4I@!@%_?8#S( ^O'(:( 9 >B6?-^D]K62/,?;=7Q!HC0% +NXQWZ0 M ="/1T8#S A M^3[)K6OE>0YWJ[C"Q*E*0#8Q3WV@PR ?CPR&F!& +HEWS>I M?:TDS_%V'5^0*$T!P"[NL1]D /3CD=$ ,P+0+?F^2>UK)7F.M^OX@D1I"@!V M<8_]( .@'X^,!I@1@&[)]TUJ7RO)<[Q=QQ^T$&0#\>&0TP(P#=DN^;U+Y6DN=XNXXO2)2F & 7]]@/,@#Z\ MKN,+$J4I -C%/?:##(!^/#(:8$8 NB7?-ZE]K23/\78=7Y H30' +NZQ'V0 M]..1T0 S M M^;Y)[6LE>8ZWZ_B"1&D* '9QC_T@ Z ?CXP&F!& ;LGW36I? M*\ESO%W'%R3V 0#@C-^10#\>&0TP(P#=DN^;U+Y6DN=XNXXO2.P# , 9OR.! M?CPR&F!& +HEWS>I?:TDS_%V'5^0V < @#-^1P+]>&0TP(P =$N^;U+[6DF> MX^TZOB"Q#P 9_R.!/KQR&B &0'HEGS?I/:UDCS'VW5\06(? #.^!T)]..1 MT0 S M M^;Y)[6LE>8ZWZ_B"Q#X )SQ.Q+HQR.C 68$H%OR?9/:UTKR'&_7 M\06)?0 ..-W)-"/1T8#S A M^3[)K6OE>0YWJ[C"Q+[ !PQN](H!^/C :8 M$8!NR?=-:E\KR7.\7<<7)/8! .",WY% /QX9#3 C -V2[YO4OE:2YWB[CB]( M[ , P!F_(X%^/#(:8$8 NB7?-ZE]K23/\78=7Y#8!P" ,WY' OUX9#3 C !T M2[YO4OM:29[C[3J^(+$/Z,1^ 3B-WY% /QX9#3 C -V2[YO4OE:2YWB[CB]( M[ -.8@5@[[^7?-^D]K62.L?)9^M2]?\&CON N=A) M $K\C@3Z\TRKR>JL[HM3YRCWLN3N^E^ M?F4/KO=$2EXI?>RZ,0/U["=D4$&=956>%3^?1T8#S.A[*1_^VZDO]!MGG)Q9 M:E\K#G/D<_P=]3V8D"'.4>]BU8ZZGGM"#Z[W1$I>"7VH>YA6KMFE4.=X,LOJ M?Y-'1@/,Z!GUA_^&C+NHYW?S?"=GI9Z[TSY-/J,Z[^KLJZDS<\T-9ZEWL'I7 MWR(EKX0^U#U,*]?L4CCGV/UO\\AH@!F]I_[0WY9W-?6LF"^/4RD[ M-.V,ZHQ5$REY)?2A[F%:.>?G3IW?MQE^\_-.G(-'1@/,Z#^I/^3,X!SU#)CO MVN0LU'-UVA?U&=693IS)*>ILIN>#&NJ=Z][=Z>>;W(/K/9&25T(?ZAZFE7-^ M[ASS4_X<'AD-,*/_I_Z ,X=SU+DSXS^;G(%ZGDY[HCRC.L_IL]FESF1J+JBA MWC75_DX^F\OLW*3DE="'NH=IY9R?,W5VW^9W<@9/S\0CHP%F]$/]X9YX>3A2 MYZPN%Y/[5L_0:3=49U1GZ3*?'>H\)F:"&NH]4^[PU',YS<]-2EX)?:A[F%;. M&3I39_=-?D_^_J?_QI-S\T%XHSJG-T MF]&WU%E,RP,UU#NFWN.)9W*;H9N4O!+Z4/&0T M<.N,U!]HI\MD.G6>$VNZR?VJ9^>T$]UG5&?H/*NGU!E,R0%UU/LU89>GG<=Q MCFY2\DKH0]W#M'+/T953;N_^[HE_^Y,_PR.C@1MGI/XP3Z@4ZAPGUV23>U7/ MS6D?.L^HSL]]5D^I,YB2 VJH=VO*/D\ZB^LLW:3DE="'NH=IY9ZC(W5F3W-[ M]W=W__NG?X9'1@.WS4C]09Y4SM39N=14D_M4S\QI%[K.J,XN95Y/J/N?D %J MJ/=JTDY/.8?S/-VDY)70A[J':960HQNWO-[]W4]^_KL_\\G/X)'1P$TS4G^0 MIY8;=5YN-='D'M7SZAVF5D*43QZS>_=U3__Z[/\LCHX'T&:D_P$XUG3J?A)IB09J3^\CC65.I:G/Y##?R7VI9^0T^ZHSJK.:6-W4_2IZQGGJ M'9ICGE/G_#IGZ] SSE/O$%7_V4KJI4-*7@E] MJ'N85BEY.G#,Z).?\:<_\^0,[_XLCXP&$F>D_N">ZM_]_*>D]WSC;!-[^EMJ M7RO*.ZHS4_69%?N@[M5A__%GZOVA>CY;2;UT2,DKH0]U#],J*=/I'//YY&>\ M^S/?_(S5G^.1T4#BC*9_2*?W-&&&?[NESW^Y:;9I_;Q*[6M%<2]-R2^MGPG] MN>T_?J?>':KOLY742X>4O!+Z4/Y9);6GWJ.E,>>L#N>E31O-REY)?2A[F%:G:+NXW0_ISGG\NYG??)O_>G/ M?'I>'AD-),UH\H>RRO3+:&)O+E+G6M';)*E]K73.<[Y)/2MGBTU?T<2=R:M MGX[]2.JE0TI>*7WL(H,U]7Y,S2<_+6&F ME?U,DMK72N5]XYS+O[CWKYHMY;,C[CMS2Y_5^Y'42X>4O%+ZV$4&:^K]F)I1 M2A:G_HUO?PZ/C!=7%_?S5TC(Q/GL5=QG6MG+)*E]K53=-'%U<#]_E81<7,]= MR7F>U;U,DMK72N5=XYC'/SEGT3U;RFL_G/;E]OZK,TGJI4-*7BE]["*#WZEW M9&)&:5FHSL@CX\75P?GLU9RS<3QSEY1L4OI82>UKI>J><3BG9 MI/2QDMK72M4=XYC%;USSZ)PMY;W6:;WL9+:UTK5/>R6PY^X9M(U6\IS/Z;O MB9JZ_\Y\DGKID))72A^[R.#/U'LR*:>;,J@^#X^,%U7)4.J3DE=+'+C)X M3[TK$[*ZN?<*/#)>7%6Y@VZ]2^5BKN%:?^GW#+IWJV5&U54_?7V>L)ZHPJ,TOJI4-*7BE] M["*#SZCW19G7C3U7XY'QXJK@ILZK*+:F7#BEYI?2QBPP^I]X9168W]=J)1\:+JX+#&2=SF3-^ MES*_E#Y64OM:5LJ?JZ83<:7TL8L,/J?>&45F M-_7:B4?&B^LTAS,Z($-O*?-+Z6,EM:\5E]\?4SCE5#5;JJ=NV U'ZLPJLDOJ MI4-*7BE]["*#SZEW1I'9+7UVXY'QXCK-X8P.R-!;ROQ2^EA)[6O%Y??'%$XY M5G,[88> M57ADO+A.G,+;T_I;)'1ISC,*/IYW-"CIX54 M-5NJIY+W(D%2ADF]=$C)*Z6/763PW"V[D]Z?$H^,!AQF-/U\3LC23^(OHI0^ M5E+[6DG;RVI..57>.U1])>]%@J0,DWKID))72A^[R. Y]>YT9)?54??=0M96\%PF2,DSJI4-*7BE]["*# M[Z3O3VI?4_#(:,!A1M//YX8L9[OAEU%*'RNI?:TD[60'IZPZ[R'J?"7O18*D M#)-ZZ9"25TH?N\C@.^G[D]K7%#PR&I@^H^GGRE^T4R?74H?*ZE]K23M9 >GK-1W4_HN.%+O0]I.I.3(3CR3DE=*'[O( MX'NI.Y36ST0\,AJ8/J/)9W-%GF>I?IDXSRZECY74OE:2=K*#4U;JNRE]%QRI M]R%M)U)R9">>2GK-1W4_HN.%+O0]I.I.3(3CR3DE=*'[O(X'NI.Y34RU0\,AJ8/B/U M!43=\7E49WC;[%+Z6$GM:R5I)SLX9:6^F])WP9%Z'Q)W(B%'=N*9E+Q2^MA% M!GO2]BBEC^EX9#0P?4;JRX?*_3RJ^"(_4^ M).Y$0H[LQ#,I>:7TL8L,]J3M44H?T_'(:&#ZC-27#Y7S>53G-+%29C%):E\K M23O9P2DK]=V4O@N.U/N0N!,).;(3SZ3DE=+'+C+8D[9'"3TXX)'1P/09J2\? MRO?SJ,[%H5)F,TEJ7RO)>2DOG@HK\^C.@NW2IG3)*E]K23/L8)37NJ[Z89]<*/>A\2= M2,B1G7@F):^4/G:1P;Z477(_OQ,>&0U,GY'ZXJ%\/H_J'!PK95:3I/:UDCS' M"DYYJ>^F&_;!C7H?$GZ7,;9+4OE:2YUC!*2_UW73#/KAA'\Y+R)*] M>"8EKY0^=I'!&>[[Y'IN5SPR&I@\(_6%0\W]3*K[32F5E#Y64OM:29YC!:>\ MU'?3#?O@1+T+J?N0D"5[\4Q*7BE]["*#,]SWR?',SGAD-#!Y1NH+AYKYF53W MJLS6>6Z)?:RD]K62/,<*3GDI[KK;]L&)>A=2]R$A2_;BF92\4OK810;G.&?I M>&9G/#(:F#PCY65#S?M,JGN;?M@Q/U+J3N M0T*6[,4S*7FE]+&+#,YQWBFW\[KCD=' Y!FI+QMJQF=2W=ND+)WF=D,?*ZE] MK23/L8)37HJ[[[9]<*+>A=1]2,B2O7@F):^4/G:1P5F.>3J=-06/C 8FSTAY MT5 S/I/JOJ;EYS*W6_I82>UK)7F.%9SR4MR#M^V#$_4NI.Y#0I;LQ3,I>:7T ML8L,SG+,T^FL*7AD-#!Y1LJ+AM)_)M4]3 MM@].U+N0N@\)6;(7SZ3DE=+'+C(XRW&O7,Z9A$=& Y-GI+YH*-UG4MW/Q$PJ MM@].U+N0N@\)6;(7SZ3DE=+'+C(XSRE3AS,F MXI'1P/0933T7ZBA_N4S?*>>S)_:QDMK72O(<*SCEI;A+;]L'-^I]2-R)A!S9 MB6=2\DKI8Q<9G.>4J<,9$_'(:&#ZC*:>"S64OU@<]B:EKY0^5E+[6DF>8P6G MO!3W[&W[X$:]#XD[D9 C._%,2EXI?>PB@_.<,G4X8R(>&0U,G]'DL^$\Y2\6 MA]U(Z3>ECY74OE:2YUC!*2_%_7O;/KA1[T/B3B3DR$X\DY)72A^[R*"&2ZZ3 MSY:,1T8#TV2GNXMOVP8UZ'Q)W(B%' M=N*9E+Q2^MA%!C4<20TL=*:E\KR7.LX)17 MYWU\ZSZX4>]#XDXDY,A./).25TH?N\B@AD.N4\]U QX9#4R?T>2SX1PNY\^D M9)+2QTIJ7RO)A[2=2,F1G7@F M):^4/G:109W)V4X\TTUX9#0P?4:3SX8SN)0_EY)-2A\KJ7VM),^Q@E->U?>R MNC\\I]Z'M)U(R9&=>"8EKY0^=I%!GE MCY74OE:2YUC!*:_*>WE"?WA.O0]I>Y&2(?OP3$I>*7WL(H-:4[.==I[;\,AH M8/J,II\/>[B0GTG)**6/E=2^5I+G6,$IK\J[>4)_>$Z]#TE[D99A4B^5U',_ MF5=*'[O(H-;4?">=Y48\,AJ8/J/IY\,>YOM,2DXI?:RD]K62/,<*3GE5W5)_^(YZ)U+V(BW#I%XJJ>=^,J^4/G:10;UI^4XY MQ\UX9#3@,*/IY\/WF.LS*7FE]+&2VM=*\APK..5U^JS3^L-WU#N1L!OJ["KR M2^JEBGKFI_-*Z6,7&=2;EO&$,]R.1T8##C.:?CY\C[D^DY)72A\KJ7VM),^Q M@E->I\\ZK3]\1[T3";NASJXBO[1^*J@S.IU52A^[R*#>I(S5_SY^\,AHP&%& M#F?$=YCI,REYI?2QDMK72O(<*SCE=?JLT_K#=]0[D; ;ZNPJ\DOKIX(ZH]-9 MI?2QBPQZ3,E8_>_C!X^,!AQFY'!&/,=,GTO)*Z6/E=2^5I+G6,$IKXK[>5)_ M^)YZ+YQW0YU;57YI_5109W0ZJY0^=I%!CRDY,^,9>&0TX#(CAS.ZF)(A\WPN M);.4/E92^UI)GF,%I[Q.GW5:?_B>>B^<]T.=655V:?VPB@S[JG)GO'#PR&G"9DUK)7F.%9SRJKAO)O6'[ZGWPG5'U%E5YJ;N9_(NJ'.IRBFECUUDT$>=,_.= M@T=& RXS%??-I/ZP1[T;;GNBSJ@Z M,W4_D_= G4M53BE]["*#7LJLF>TJGWCMG.P".C M :<9.9UUHDF9,<-GTG8_I8^5U+Y6DN=8P2FOJCMG2G_8H]X-IUU19].1E[J? MJ7N@SJ,RHY0^=I%!+_7>,=L9>&0TX#0C/LQ[)N7%##^7N//N>KQR&C ;49N MYYUB6E[,\'-5.Z_,+*6/E=2^5I+G6,$IK\I[9T)_V*?>C^D[H\ZB.R=U3Y/V M0-U_1S8I?>PBAW[JS)FI'H^,!MQFQ(?ZN:DY33W7))7[KLPLI8^5U+Y6DN=8 MP2FOZKN'FE-I>S*!.@-%1NJ>INR!NN^N7%+ZV$4._=29,U,]'AD-.,[(\JY)JG9=G5E*'RNI?:TDS[&"4U[5=P\UIQ+W1$G=NRH?=4\3]D#=;V[,4XM'1@..,^+#_;G)&4T]UQ25>Z[.+*6/E=2^5I+G6,$IKX[[ MAYI1J;O23=VO.AMU3\H]4/>HR".ECUWDH*'.G7EJ\=3 MJMSQ"7FE]+&2VM=*\APK..75=0=1^DK?E6KJ_B9EHNY+L0/JWE19I/2QBQPT MU+DS3RT>&0VXSH@/^'O3LYE^/I7*W9Z25TH?*ZE]K23/L8)37IWW$*6MF_;E M)'4O4W)PRN26/F_(8 IU#I.RZ*;.G3GJ\,AHP'5&?,C_S"&;Z>=3J-SK27FE M]+&2W-L_W=3K"4YY==]%E*YNW9<;>JR_NGFWH]P2FO[KN(TA7[49\X/^36Q9NYZU2O2GO):JWV)O[JI*Z-ZIG]BE]G*#. M(C'33ZDSNSE[)1X9#;C/B ^^[P.C^]EW=>SNU'Q2^OA->G]_NZ7/4YSR4M]- M5%^Q-_=5)75O5,_L4_HX09U%8J9/J'.[-7^$'I[JZ'EZ M-BE]_"9I5G]R0X\G.>6EOINHOF)W[JMJZOZH^MFG]'&".HO$3)]0YW9K[DH\ M,AI(F=%M%T%2KTF]O-.UI].S2>CA3Y)F]2?I_9WFE)?Z7J+ZBOVYKZJI^Z/J M9Y_2QPGJ+!(S?4*=VZVY*_'(:"!I1K=<"&G]I<^L,$=1:)F3ZESN[&S)5X9#20-*/TBR&UM\2Y M=?IY8ZFY3Y3J+.(C'3I]39 MW9BY$H^,!M)FE'1))/4RL5?''JK^K6[NYW]']=GMSLCAC),XY:7>5ZJOV*/[ MJHNZSXFESB5EMI.HLTC,]"EU=C=FKL0CHX'$&;E=&.KS3IB;NN\GO4\XGT-. MG1E.H][EKHP&0TDSTA]>;C5!.H,)M:TG";.>2+U MWG1DY'#&29SR4N\KU5==U'U.J0EY=%-GKJY)>:3,=!IU'HF9/J7.[[:\E7AD M-) ^(_4%XE)3J'.85A.SFCCGJ=3[4YV1PQDG<DL[C.H>J, M',XXB5->ZGVE^JJ;NM\I64\Y!W/OSWK:>1SG.9$ZD\1,GU)G>%/62CPR&KAE M1NK+9&I-IYZ0\Z2S=%'/8$K. M$\_D-LNIU+DD9OJ$.L.;LE;BD=' 33-27RB3RH$ZH^FSF7Z^SK-/IMZGRHP< MSCB)4U[J?:7Z2D7=MSKC:>?IHI[%A(RGGLMICE.I MKZJ,',XXB5->ZGVE^DI-W;\JVZGGZJ2>CRI7AS-.[F'2#O]&G4]BII]2YWA+ MSDH\,AJX>4;J2X8+[7/J_";/A3-[['?"KE7WE,XI+_6^4GTU@3H#1:Z3S]9) M/2=%IB[GG-K#M!W^C3JCQ$P_I<[RAHR5>&0T>4EW)7J=Z:1)U%9YX.9^RDGEMGGDYGG=C#U!U>4>>4F.DGU%G> MD+$2CXP&F-$/]:7##)Y19SMQ+D[GGWBF+DE[YW#&29SR4NTIU5_3J//HRM+E MG)W4\^O*T?',DWJ8O,._4>>5F.D[ZCQOR%B%1T8#S.C?J2^?F[-_2IWSQ-FX M]##Q3)U2=L_AC),XY:7844I34ZESJ<[1Z:P*ZGE6YN=\]@D]N.SPBCJWQ$Q_ MH\XS/5\E'AD-,*,U]45T8^;?4N<^;2X._4P\DX+['CJ<<1*GO#IWD]+6=.I\ MJK)S/;>">LZG0"8$5YSW*WU.&1$;&XF#PP'P ,CG_?QA?> &@EO*>Y7_P_C""P#U>&#,PR,C +S@2R\ U..1,0^/C M #P@B^] %"/NS8/CXP \((OO@!0C[LV#X^, /""+[X 4(^[-@^/ MC #P@B^^ %"+>S83CXP \((OOP!0BWLV$X^, /""+[\ 4(L[ M-A./C #P@D=& *C#'9N+1T8 >,$78 "HPQV;BT=& 'C!%V MJ,']FHU'1@ !XP9=@ *C!_9J-1T8 >,&78 XC[LU'X^, /"" M+\( &0$ #@!5^$ > LY;W*W=J'1T8 >,$780 XAP?&>_#( M" O^#(, .?PR'@/'AD! X 5?A@'@#/4#(_=J+QX9 0 . %7X8! MX'OJ1T7N5!T>&0$ #@!5^( > Y]8,B=ZH>CXP \((OQ !NI7X4Y#[U MQB,C +S@2S& 6ZD?!KE/O?'(" O^%(,X%;JAT'N4V\\,@( # M"[X4 [B5^F&0N]0;CXP \((OQ@!NI7X$L (245.1*Y"8((! end XML 9 hqy-20210111_htm.xml IDEA: XBRL DOCUMENT 0001428336 2021-01-11 2021-01-11 0001428336 false 8-K 2021-01-11 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover Page
Jan. 11, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 11, 2021
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20210111.htm hqy-20210111.xsd hqy-20210111_cal.xml hqy-20210111_def.xml hqy-20210111_lab.xml hqy-20210111_pre.xml jpmhccconf2021.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20210111.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "hqy-20210111_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20210111_def.xml" ] }, "inline": { "local": [ "hqy-20210111.htm" ] }, "labelLink": { "local": [ "hqy-20210111_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20210111_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hqy-20210111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20210111", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210111.htm", "contextRef": "ib3dbce357db4416a83f28748169194fc_D20210111-20210111", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210111.htm", "contextRef": "ib3dbce357db4416a83f28748169194fc_D20210111-20210111", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001428336-21-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-21-000002-xbrl.zip M4$L#!!0 ( .M(*U(0*M%(_Q0 $V 0 :'%Y+3(P,C$P,3$Q+FAT M;>T]:U?;N+;?SZ_0S=P[0]="B6WYF;:?AU]0(W;'(8\RM)-PFG&&+ORLCTX83X?(2^(0G<3)T#^G&.=M=N+1)/'/ M^AE2)$6^5IC4/572*2$6EE7#PZI%3&Q)C&++\;CLF9XA4V7SK.YYLJ,19D$- MU<&JQSU,N:Q@9DD>9ZXL$5G99'7J:E3C!G$)EU2%:I9J4:X3HBE$,W55$]WV M,Q@=C#!*Z_[EQTH_RT;U6NWBXJ)ZZ21!-4[.:HHDDYH?!7[$Q9 K975X'M[6 M0"(U4>S0E,^JBU+_COI^E&8T(DI!FLHQB3AB4%*WH)Y/:>Q S-D4K]515A '+M[_:7([?/0XJO#P7PPREW MEUK"<_4L/K\711,3>0:'\:O>\S'.@$"!J&YA29Y5KP.N;?WG/__YD/E9 MP+?Z_TRPH%I)EN4/M>+=AUH!V8G99.L#\\]1FDT"_K'"_'04T$D]BB,._?N7 M=5&1)\5/GS$>Y3^AW 8&2GRWZ/XR.^3>QXKO$.:XG&@&T,4-ECE,%130477._WHP O\D.C":A02MB_/(O/JD@GP%H1KY-G$9\ M_D4Y/.^2]I@-FN>]/6NP'^X.[).FW.NXT^[4#MJ-@TFWGQ M!/ZJ]N! _D+LH#L=];O3;WW[Y)BTE?:TU]F6VF%3WN\<:-V38WC3EMN#MKS? MZ$KV-U/ZHO0FW1-7MPV%7NO-X!V6F_O,.SM'4SV&]_"=N-S MT)X.S]G>KN_L'>OMD]Z@!^^Z2DNS]P!>XT"UE<_#=N-LNK_7\WL#=])N#)5> MY[AL\PWZTJ)>)[[LA?:P'7X;= =#J37.PWVFHO_!S:T];%?J<7 M (Z3+YUFUCZ2+K]TMD\-5[$(TPVL4$,&4>,P;%DYO-L@ M-E6F$X/!,C-85H\&*;^QHK5EYDVXQQ,.DBY=(7*$A*ZGN42$-4>YQ*YG(&@^ M5E(_' 5"/.;O^HD@B47I4KU, 84/M6401?=7?98HI/$XR9]R#5,OR:R@B:>0 MV0P0ST7([,EGXMGS>8)RA/A*:;[3^FN9(ZXWWIJ]6H8^@NF-V>P)M$>2-<": MV!)(":$N!.[ULCF:[):JLY+9\ZR3VM)$S69U/HVU!5E= XE>B/5\.N\S*$[% M[%VU*55!Z$>XSX714U>5JJ&-LO<7/LOZ=5F2_J^25]WZD(XHT)23U ! \;N M# 33P#^+ZB[,+$\J!<19(S<.XJ3^FY3_>>_! MR+%'0S^8U/_83GP:_+&9@NX%T(GO%<6I/^5UV01<\\>+ G\#6@M]/1N/K*HP M@F.[U6DVT%%GN],\6D9_ ?$?B^-1<^?XL-5I-8_0MMU S;]W/FW;>TVTL]]N MMXZ.6OOVBR,N/0CQ$YKV_>@LBZ--U*CN5,%PUE3KTSK5EX_.@/;7[O? PV._T0WOO>-)KG"F@(8?=*0/-!^]/ /[ M!$ M*> I765;[XM MFVK[XI00U;(")59]Q&9 M+.0L\/]AT^Z@P^;7_) M=Z?/!;[CQ,]\,(::EVX?;"&.MMT,<$8RF%S_*EH2=H48V"$?Q4F&-F;/G()E MP=,,\7,1$TGR8L[>_5L>OK9Q?4A<\/K2^S.H.9# %BG]')!*:31ZL$^=?< ME&L6!M[/)=$G[<'Q*5%TV5&HB265@R,C4P\[U(!?GB/IW"&J8]#*UF<:C<$Z M1+*\F8?;UB[?P18] V/7B;,L#NLZ4-,J0!EU CYKXL0)6-H8"#:@HY379S_> MSP(H18 (YXW>G_,D\UT:E""S>%2:TI95-34BB#,#LSUC,_"EH5W-#>U:QFZ6 M*5:5%"U7%DM5^=:RN\ 2HVI9RK.#S;'5'@2VEL]$,JM0LC 9996\'4RT6,6/ M%5*951E1QL#4K$M(SFO-NEA1M5PV6( ZU$5I'/@,S>3-(^"LK%IBOMS&NM%& M&5V*5HLT%G ONTXD(?CK :\L$6H) HOZ=:6J")]L]BX/3\]>KDG0*NI]DK9P M#=<=(#SD9WXJXJZ9#25O4I 6@:3]1C"PIZX,YH'EI-[I*+VP1$7"R.ZYF MAY_[O48P;"NMZX$D=?^D3>SI-Q"TAV&[TY3L02\$V"!\CV5[.E2ZX>YP_^1@ MV@U,$4":!Y((XQI,.L5C.JM.3POQ3OEE)Z3>Q;RP7V^BV>1VND5:S_@EK*D(RG:"DB5XW" M^'JT.KF[3"-KT'UO#EG],1KU/F9XH%X"LGA=2NG^@-1ZE-*"^2^"FR+$F_%1 M$I\+;;5L_Q=:JQ6Y<0*>5;Y/>"1J[\3C*$LF.S%[RTJL-P!XG4-05+V!W0$\ M&]U);V^WWQYT20_Z[X9B%Z4][8;-:TIL%-J=[J6]MSNT0\#GI U*#/HY:4[R M79D.]-=HJ8"/W_UF7BPJ,9-9NDPLA@V%:UBUF(9AZ1QL6)IF484JFL; W^4! MO0!G[ &JZ[O5TR(;*559647PJWGI#?/ =1+?]0,.T!W@[5_T?#\]M^;TK*B* MI,NJ@@V3$*P25\86+ -V/0-\9=/DS/#$%I6,B:[IYJT$_>RD_$LC/)T;.O2R M56XANKG0_\4:#V:-@RM13U6#6XJ.35>SP%\A,HAZT\*F8A!#9:ZBN> F:PI6 MB$ED_68^PZU^RC/1?V&EORX6N'<#*^> C=P*$7'Z..OS! W&B9\ROPC@WQ&T M?QNC\Q?MK7R0R1F-_&G^_&[=-L"_FW!VXC#T4Y%;B83.1X5D^S6IWS6IK>IA M]:B*FN$HB"<\>>/LMZSZ[J"0NP,O92A$A&S)'4-Z6$#E/BCKGACE1>R.;<82 MGJ;E?U\ ?E-VAS?L=DT=4\=3:6F9IG85647JQKQL,5-,*X-C^O$-515,2I; MLH9.Q,[G$= !+,;7V(?50(W$/[_A-3Y^WVG=Y+2>?>B\,?BH0I43AVP(5ANFQJK@8>3".A(Z'TE^EF\_D3S!X= MN"S7,'<6]I.O4-//CTG\9 LY/)48L/Y/]2LF\BT+K!6'CY".0[ M$CR[B6C$4(<'?"3HI72R%VL*[BZKYHF?L\29WW\S%=EXGZ*O"53V1S1 S4ON MCC-P?-"^!VX[3]]*_N?#YM&.,[0]&@6^*R(-KQ/'#7&D@">Y,! 12Z]XI',* M\%"1HLQ0*FPP%-!TEJ][^VK]N/Q&8E4EHCTE<\0RJY9T>_'W90P^*97HP6&J ME5N_3\G[$2&\!;A:CLL::%&]3HO$% D*"8]+MF?.V>GA/'@4-A C-8QD63XR3Q,U@S$=4? M1V7$-OVY[ [%'KBGIJ)I*E,))D1RL4HL\-1E#3QUKDJ4>!JAIES9^OTWRU#5 M][>:'2_&HN6R :4LKAL:+1S'.1R#4%<5K>2D;/G$BSCHLB$;:&?W$"E$JD+% MAZJ1GYE=CD!;N#"#T5D;9*)8QI^+5XC=Z8*-;BF4R 13[A"L.I8,OYB&)4W2 M*35U:DGD%?'*U9JAL%RTFXPBJQ3+R@*O+!T)FW.*"N9'7O,7L]S/+%\3+O2* M./N?'V85ID$"'L;/YMBJ=J-[:A)7-R5-QL1AX-CJ3,6F#EI&EPW=8AIC1#%? M$=/ VF%W8?'NU32RRK"RX;Q[& L5=7\QT:.9J)6F8Y[\M*RDB4BOPYBJ.3+% M1#54K$HNQY;,3*Q+Q#-G0PEH>Z:"]\-/.IAUZTJF4][&C&H\Y0JH#0\X/-L377 M?)!D=?K[/%7KQ7*2.N+VL^+$N]M';D#3]!&ITZ]Y8 G-P[U'D]")@XV%T.V; M'I:=QT'+Y>(SZ0<2Y*+OPYLK,;,TW'OH]$&'@%_%I-R0L^O.6R]%^$16G)Q5 MWJ194::J-]IJ6VE== =_#GJ-/Z&-[?=.6EHO/);W3PZ@S/:[81MP/;B>JCYL M3\^FT,YO[]G#-I@B7>4SP ["'HP-^IW"L]^=#B5[=_EH+=45#6P/,.J K7(:"0N*^O? M=6SI.P^X_YRT78K(0D+^(NP'$/;5Y8.2*1%5E1BV',W$JDHH-B7=Q)I)#(5R MIC#N5+8^'71_D>SS.X5"[]U,S9J)ZIE/\,9O0G@YJKXZ=$<4F5'=T<5MFB+: M+WN86M3%FJ=2ZDB>9Q"]N"3*WCYJ;!^@O2 &[QS+0C ML55'4\2X!UTPY$?E#H2DS?R]:]L/Q3U;9.[._OZ;K!OO\\T(27LG-L$% /%6 M>@]F"5:*GS>!K;J]:P:U:%."%OZR /2N6KQ^5X+F*5,G!!WROMYK*RX_E=P0MY7,!&=YU\K$-P>\0LA M(A-^[J?0#H0NC5S!T=1UQ>42HK*XU9[1A*5%R@2[+2A'-N@\*+$!%,8R?A=(BI!Q-4I\$%G:25VAHO@+ZY3@NLK#\7*]]_]#\/ M5;(TW%R>]K@#QK>ZDC\?H2N7Z*X MB3YQ&F3]YC]C4)2;J!6Y5;0A6+TRTY/OP*Q+QR =* @*GHHH?L!I*I),LXR" M3&/"LFM>]GW'SY!E564A/K(^&(-@A"57-X>* -TL+4QDJ$8@B=P\-RP#T9=F M?IA_03H.H(*0=**B!Y,.8D340E!+M)\-BI2#RK-?LSX% M@S0#F1@$B$&C,: . TOY'*2H-NL7;%.P&$MDSOTD&XM$ *@)^!<+#N#$O! + M9.QV%(GRS]6O5=3.SX^7\^C2A*.=."IOM1=#GD\YF4TY0-+JBH2^ME&3BD!E MA#I^R*MH&P4BSY:.F1^C"^ZX(HVS%+W+N 3Q7-R#_!_-\^#*1?LC7:X_3VW( M/V(C*KI7..8SY$"WY]0/\BV3K)_$X[-^7M&/SF&.8/*%=)A-0MF-P!&$$*\C M/ZGV\PG@.2%502=5WP93=/(QSC_4(ER3)5H&,G:X( QOG$1^VB_R%Z\Y&8*2 MYKIQX1"\>)_VP3+-53K,,>-@*3 DTJP5&(L?<);_EM_G! X*&,0Z (3EG"M@ M>>P[FF!SR8,)2D'Y2^.Z>I>!7@ :V?^:0C3-3CE[E,$BFD/!-3"!P!?:/V>Q\ZNTI+R(0%(\%R6^#FQ>WTUMNW M;@3%?SG33W:F!0T\S_FBM=W(ISS(!CIJ[=G;G>/#.S['], ]DU=QSNJ!%M'B MUU.*6"&P5E(:> _U"%8$&=D8K&67CD5@,/?22^\"VM#Y4RCU7S$-(DWFF=?^J0E, MKV1&7AM1K$^,KQY_GNCZ8\7!2P_YZJ:/;[[+D7#T\F_=YN'$G;[//705;2PN M TEN$L?C7+@WYM_5BD^CYY]3W_I_4$L#!!0 ( .M(*U*[@]HIC0( '\) M 0 :'%Y+3(P,C$P,3$Q+GAS9-U676^;,!1]SZ_P>)X!AVPMJ$FEM9HT M*?M0UZI]FPQ<@U6PB6V:Y-_/)F$):;LUTQZV29%B7]]S[CWW^H.S\U5=H0=0 MFDLQ]8@?>@A$)G,NBJEW<_T>GWKGL]'H[!7&=^^NYNA29FT-PJ +!=1 CI;< ME.@V!WV/F)(UNI7JGC]0C&<=Z$(V:\6+TJ!Q.":'JRIAD_ MC:(8D\D)PY,X M.L5QF%,Y6J MJO>/ K><4@V]>[E8__ N@5:FA$7+S=K/9!TXM2$AQ$/4&,73UL![J>I+8+2M MS-1KQ:*E%6<<1*P>M&*H/$(^A> M+4@O\@ M=02E F;1BS7N-_"WBJ:^3:3W>,0_[(9;#BP$JOE.2(\UZ\9BM>U%!9O2_,6Z M,UH=J]M"LK;JNOROJ\^!':O>0KC@_X/X1L&QXBU$VW?C=WKO\-=V'?%\ZEU( M^P7PA18V/6>_N?KP_!O3!=X!>M:>=]>/66@?6?M#>/?1@%&'1 YZ%AP"#JA: M#?EG,>O&ATJWX*W+3X 'I^/%N.&^>A*V-?:5W%ZQP?".W]S4-"@L0<6(9%226(AM%\-D+17NE#%8Z:.T#S<-I%0LW1R(MDL$/JU#FMZV(-$X;[9?[E(=L![ MW\']2?ESVIB!!(!LS?P=OO$VM!O3_?D(Z\2IX=A??)T%.=>Y/^/PK)2QJ/GV M.9<\RS>\;TY]G'8WVX\5@M;_=0*3!RU !(T5^>W!-XN?4$L#!!0 ( .M( M*U*LL?J"# ( 'H& 4 :'%Y+3(P,C$P,3$Q7V1E9BYX;6RME%UOVC 4 MAN_Y%5YZ.^,XX2-!0*5UFC2)21-;U=Y-3GQ,+!*;.J; OZ^= H72:M.:FRCG M^#WO>6PG9WR]K4KT"*:66DT"V@T#!"K77*K%)+C]_0TGP?6TTQE_POC^RWR& MONI\78&RZ,8 L\#11MH"W7&HET@87:$[;9;RD6$\;8IN]&IGY**P* HC^GK5 MC$0O'+ X3C'M#07NI7&"TY SG&8"J$C$D++H\V(D!,WZ,4^=HI?AG@"!&= ( M\S04P',:QB[PIJ54RY%_9*P&Y#:GZB:SEVPO])F[4-$U3TJP>I;5\2^AL*;G_,?N5%U Q+%5MFCO_?DDJE25<5F2O(:PL'7'C8'F(-@Z]*V2'SIW2JOKIAL\X OK%N@ M;8QP!54&IDW4,]\3S@/D:\("6&D+>%A+N^OFNB(-WHUV<_@G6\ _H#WLL)^G M(:7-'WSU4GO2WMVS5-*/CID+]P:^U?^!P-:"XL #)/DDD$/&&(UXW.\-!GXJ MLR2').2")5$\$/W!GS.F,3F;S-/.$U!+ P04 " #K2"M2VSEUN\<* #- M8@ % &AQ>2TR,#(Q,#$Q,5]L86(N>&ULS5UM;YM*%O[>7\'Z?MF5.C'S MPLM4;:ZZN>TJVMRV:E/U:E'^*GH]-D[OQ(TI_1+P; >7'217+[ MF$;3F\Q!+H+;WZ9O-'%]AC$%D 0:$(I#0%W) .5:01WJ #+T>OI&:\@]+*FQ M(!P0K31@"B(@J:N5%-#%YDWN=!;%/]_D?SA;*,PL2:=CY+IXO+8>K%')V_,I=D5XVIFT!?>LL=;]6ZT MB.:W,[7^["95NMKM+$U+7G.4-$<)_1SE;W7!QAW@'PEOMHOU"."*=#\="^,^ M3C\=#>ZUJ0_J]( WPG2&O+R@/L2RKVOW*51GZ*='?*S+(LG8K(?+XCG,!N19 M_L&5.5J%R1WM*:9%G%7IWH"J'C(52[6LEB773B3?CAGV-!72G61/%_5$Q>#[MW7\(LB! M"".+W+(:C:9JD=REXKF[S6=5+.8S=7BEJU.,##S@< 2^?D*I%-& M^7;\G% ;&F>G)VR(.Y_ZLK86!722^4.)LFOP:FW,- M 9#F!R _ "Y<#0U^J_<[WOD!WZ=KM"P5![A>68Q%8D8[MQDHT9Z/#ANFE24- M?_LE@2;LR$E2J5(S@JU(H70-?DE5[LL,)5!-)>2AY& #/>*2<0PBK0J(!3T=*DF3*+V5%(N4-VN+ MS6EMB\Q[*A<"G8]]RS_ MVM1V)5]O:B_S;\DL$E$6Q=,_3>E((S:;>*X7**P)4$1+0(2' 7JXX]>?5R%<4*3@1#D/C(!2%C"A NE=&L[P%)L1LR117Q&T_\:Z,,3;K; M76=UX.1@G<^Q]E5]NI*XU; M]&HE[E+C]<.#N#&_KOID?O$)"D*M*$: (426$WU.J0\@) '7R!0%[#7NUA4! MAB;Z-49G#=+)45JT["H2&S3MCM2DWJ5W5[GMKWOO2:K4O_?9 M':^#HXD96E-)10BH@!@018VB96 &X0Q"SB4+-&-=.S@:FICW]J7K^Z1[!T<= M.K@572_9P?(D3WD2IA20 /45/&;CH++&4BF[@A)50S 3@29IZ,& (A)@AH M37Q?(QAP#AMK;M/SX$27@W-NV52=62BNQ%4#R;5EX-2:*Y+_[QK9_XZDNJIL MN\BNY*\_W56E41)>I4';L>Z%BHVCV64LU<._U>.$\ !RXGL 2Y$O4>$,4.D% M0&H/4M?UN2NPW3AW*\+0E+@:N:U0.@5,Q^"T'=MN$]ET7-N!GG[&M,V9:3&6 MK5\S1XNI?$9Z=5*MD]WCHQ]Q-V&BA9QW4^ZLX V7/8MV M-YE=G5;8V$MS_<3CM3EU8N:]1,B Y8P(0 *% 0NT!(&F'M&""\(:K^[8=#PT M23X]YIF#:Z[&$E>'E=B6@1.KL%GR5@*LRK2#^$KN>A->51*;HJO\OFTO_#!7 MZ32*I_]*D_OLYB*9W[+X<>)[Q!6:&3)4J$Q;E*8C(HH!=6$@75^B4%JVQ/L3%@_/=26JQ;]="\3G5MKM?>>N^S>%'<; M[G[S]FLV(.+74393$R% MAR;/)W!.CJZY*LMT'99D:Q).K,>&^5O)L#+7#AHL^^M-@)5I;*JOVL!>>ODN M,K,O-TF\OOL!/86I\A7 R&. 2"X!Q2@$2BJ&*:=8-5_/N.U\: (L\#D%0.O; M1CO$'=9A%SI.+$4+)JSD6)=R!T7NN.Q-E'7);.JRUJ;C6L7BR<+/Z9*AH0W6JYXE:@H4EV>QW>TY.P:\ MERQN M\]MT+MN=M7XFLRT(:[]RL8:-8RU>W';_,NL7:Y*L7<)89]^Q,'Q)%AF;_2>Z M+9;I^9HB%IK!LM 2 8*IZ=X<8> R1JGBG"K=^.YR?9BA%X4E6,>@;;7#0"6S ME@6A-5\]EX.F5+4O!I5,'*L4E)V_3"&H3+"V#%1;VQ>!ZY3E6VQ^>YSS9#:A M%/K29P+X2@LS)O#-G#G4'@A\Y7+H<2$%::K[DN>A27T%SEFB:Z[L,EV'Q=R: MA%/?PVJ6OY5<*W/MH-"RO]Y$69G&I@ZK#3IO ':Y6-RI='.[*LFQ@MIW 8+, M#,DU98 I'0 7NT0BW]-:-U;CH6!#$^C.'E=+Q,?9$VR7ZL-*/B:!)Q9W)^ZZ M;!-62\KQ-@O;#?%26X;5)KMGX[#Z<]HO!WG:]?4/,S&82,U9(%P,.(1FY.X1 M#]"0!8 S25R!I >#QAN&54886J%X6B.Q1.D8F$Z.TWZM2)G(PQ6A,STG+@/6 MS+1:2%*9_1%6E)3]]KZTI#*MJC4FU89M9^-?U33*G]B(L^*!=L]CBI(0 2X5 M-?-P5P#NX1 HY L8"B]?I6TW#R\'&)J85]/*9Y"6NP)4DMATRMV>FGXFVTU9 M:3''KDZ]\^QZRVW/\^KJI'9GU#5V=1+>Y/W*')V_6G\2+?__@_-7_P=02P,$ M% @ ZT@K4L>L8$K=!@ D3, !0 !H<7DM,C R,3 Q,3%?<')E+GAM M;-6;;5/<.!+'W_,IYF;?GAC)>K!$)6QQ;')%';NA$K:R=6]<>FC-N.*Q6=D$ M^/;7'B#A<=?'N KGC9GQR.[NOWYNM]KFS<^7ZVKV%5);-O7;.=NE\QG4O@EE MO7P[__WT/='SG_=W=M[\@Y __O7Q>/9+X\_74'>SPP2V@S"[*+O5['. ]LLL MIF8]^]RD+^572\C^YJ##YNPJE23"<$T,#988 M%X%%'7-FLW\N]V)D3O)@<(1P1$2(Q ++2# T0O",=K7UOH"WWVLW.X\;;;J/YW_HU>W9$_XW< M#B/]+H(R<+9[V8;Y_LYL=BU':BKX"''6__W]X]$WDRNP5;>"/\_+[FK7-^M% M/V!QV" .)W;9N[LYO+LZ@[?SMER?5=_VK1)$/,^?5Z2?5LK8QN9/WX]=?#=_ MEJ!%8C;A'N..FU/TQE[F"EQV4 >X#O'62M7X>X.J7N FW1Y960?59F\1H"PV M9SYP;9>L[PH3J03%)3%>*R*84<0 #\1I[X JYX/0#R)'MUOT>S,?+?C=9?-U M@2?&>6&F_T#Z#X2RF]GXZ9'1:X5>YOWM17B*8PL*C%*544*5D$0( 7@%*<1! M,0S$@_!!C>#\79OW?;\[OP?)SYH4(&$NN35JD[\WUX\YOAFQ.+,)3T3\JJS" M[=%]4AECWKIF!/VN)P?=G<\PZ@@I03B^GIMG@]M$UF&&A;]!%+9A'=U M^ 53<.%U;CV7EE";!\R-UA",WA-A+<5$%+G+PX@ W#,^B(1L^B2\7-%71N)= MW6'*?%]6\-OYVD$J/+7>,*<(1".(H"Y')9@G,A?.LBBD<&.D@X=V!X' IPO" M5CI.@H&/L"Q[$>KN-[N&P@;#(5I&((2<" F&:*XLT8:RD$7A8LY'X^"^[4$L MB*FSL(6>D^#A",OX=-:DC?"?4'\X;,[K+ET=-@&*$*12$!@Q%C(,1UCB+ BD M/:B0>Z BQM'P^$M7!M$BIT[+>&I/ IY3>WD44+XREM?KE)NLF.4.G(R,:(L7 M@+ ^)]IG 0.QG$HA9<;'RRK/.#$(U8,90>!*H'(2 4]#>_,$%'K"""B:B ML)Q(1K&FS@&(RQ%ZS@$O Q>U#F(T3)YP8! B^=01V5;9B>*1%598I;3CQ&>F M[^;@NLOERA"EI#;!0Z9@O)O/$PX,PD/_>'C\?\I."8]#_/@AG387=<&RC#J# M2$O*^XZ@]<3ZZ'%BA952^^ <&QN.[^8'H6%^$#1>J.J4P-B44A_226J^EK6' M@CNO!8N4Q" P#DD%T:Z"4#IP/D9/['D/AD$RX1[I2.*^,B)] M!CQ(8#=^^Q"I<=01E7M+1&8TT3)B!-Y'XZP)@8]1=MRU.0R#"3=(7RS@*T]\ M_WRM.EDU]6T_CQHM+#.XYA:,$J$=+L$%I41SZ0+D5CLWQLKUH=UA $RX,;J5 MD*\,P>=4=AW4A\UZ?5[?++/;(H0\ ^88R;C#)90"C4IXA\* T"KPG.5C+$Z? M-#X,APGW1K>7])69^-14I2^[LE[^BH5/*FU5!,V9RK'&418%$5Q3X@+6/2Z7 M%H303,4Q'ID\MCR,A@GW/K<4\Y51.$G0!O<]&(;&A+N<(XD[+42.VO82 M"1T)#9G&6EA;HG.N"?B <2FOL#(>'Y1'?@S#9<(=SU&%?NU;#/ASO$U>L[?3[.][Q9RK)NQ9-(9PQ1IN(H",R:P,2!Y:'<8%!/N2><^)]E@=">-#7QA)HER.MT!J75718LTAQ$P"6UI"B# MC8$8)SRQ6E'-HZ,ACE%&W#,ZC($)=S!?+N%H<_]F\4B\8]RQOW/S0[_I_X=C M?^=_4$L#!!0 ( .M(*U*4-*HI,Q %E- 2 :G!M:&-C8V]N9C(P M,C$N:'1M[5QK<]LV%OV^OP+KM-ED1I(EOQ_9S'AC=S?=I'$3;SW]U(%(2$)- M$2Q 2M;^^CWW A"IAQ-WQW;:&64RMD2"%X_[.O=!O_KK^8[M&['5WMZ^WGVSO7U^=2[^=?7^G=CK='OBRLK?77=EN< MFZ0:J[P4B56R5*FHG,Z'XCI5[D:TVV'4&U/,K!Z.2K'3W>F):V-O]$3Z^Z4N M,_4ZTGFU[;^_VN9)7O5-.GO]*M43H=._;VFY>R3W]P>'Z?'!\5Z_=W2LCKK[ M1P,Y..SN[NSO'__2PR*W,=P_X\I9IOZ^-=9Y>Z1H_I/=@Z(\G>JT')WTNMUO MMWC8S.)A_]'36*4D[1#$^J8LS1@4BA(4]'@H9%9B>6,Y5+]T>[+S M:S'<$LXFJ]<\G;":O9WB]G21YC[6-U&VU(G,VC+3P_RD5+=EN!V6OK/?+6[7 M[92'^J<2G*:R6W?N[1Y/Q?N)R8P]>=;E?Z=TISV08YW-3OYV9K7,_M9R$*BV M4U8/_&VG_ZM.>G36_'7JMWN(IS.=J\B,WGX/'/B7PN&-+GZK=#D39WENJCQ1 M3ORLI&U?Y*GX)#-\_5"5$,2;EKAS%ZN\.?VZ&[NTRF%628HF9"F^OQ3OH5DR M%W[+B;0*JI$/E%78\CTW1G,7,DVA9FWKI:BSSW+X$#OKWFMGYU86RK;$?THY M$L^?'>WT>J?B1=S 8ZQC;^TZ_OGNPS\NQ \7UY^NWWZ\>,SYUY_#R_GFOY=Y M)>U,]'HMMG%/?Q;SI33UJ27>YDE'O/CA[-/YV8_/G^T?X?Z//[\4+VCT3O>T M.9@O@8"QHAPI$4:\,>-"YO'FRQ;?RUFH><;#4R05"=DDD"QRWKB3V?/G^WNG;X42>5*DVJ9@[1)Y4S(8 -2H4LQU5DF"FLF M.E5BH.&Q0)(, I2KRDHG!EBNIM_:P62*&XKZUK\13JG0%O"#%V9$N3/_#;63XN=$TG,&\5A MMQ?G)1)6:L>[PF3>G#$9FBB1;B1F6F4I7UK:S$YG@:OP-LXL')-;,2X-PR(F MVI:5I&-L&"1L6_&JP!GE7.?_,#^9&I0G6-S^BDGJ[?)%MK^:Y>&DW3MZ-"NU M7B."0CRU*BX>3V^GL[='&[\(@I8VI4R0"U"WA4KH1FE$7T&)A(2HY$.%;^54 MJ5SL=PX%5IJ-GY3:_7V9^/ Z(@4PRC0S3H8V$U; >Q^6'9N[?A M[AKNLLG6[@NL/5[B[#%4N7\?W?WFJ#'R,95WP]UUW-7Y!-" 0M+[*##"Z@4N M[W5ZM?JJVR2K&!FPDIH21+%PH0&LDM)S&XR[4:68F S>.2,?/P@PS*JQ)+[8 MJ.5C;&I$7Z+L>+E)"*=9O\!O=FKSL60GEI!%=R-+CRQ+3=Q6@\V(;)/,.+6" M77$/+%Y"G! YEH]G8/3+FQ0A $0DW&% M2#@"=P&CG(8SH'>Z) M'+#.V!L'6Z)O MS0UC28SJJUP-L&B93K0SUG7NFR_YH_%A4%D(E&U$.

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end